Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tom, C.
Right arrow Articles by Kane, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tom, C.
Right arrow Articles by Kane, M.
American Journal of Health-System Pharmacy, Vol 56, Issue 9, 865-871
Copyright © 1999 by American Society of Health-System Pharmacists


Articles

Management of toenail onychomycosis

CM Tom and MP Kane


The treatment of toenail onychomycosis is reviewed. Onychomycosis contributes to 40% of all nail disorders and appears to be increasing in frequency. Mycotic nail infections are usually caused by dermatophytes, yeasts, and nondermatophyte molds. Most cases of toenail onychomycosis are caused by dermatophytes. Mycotic nail infections do not always resolve spontaneously and may have a substantial impact on the patient's quality of life. Current treatment modalities for onychomycosis include surgery, topical antifungals, and oral antifungals. Surgery is generally not recommended as first-line therapy. Broad-spectrum topical and oral antifungal agents are the most frequently used treatments. Topical treatment is well tolerated but is usually not effective because of poor patient compliance and inadequate penetration of the nail. Oral antifungals are more successful but carry greater risks. Griseofulvin and ketoconazole have been oral antifungals traditionally used for onychomycosis, but these agents are associated with relatively low cure rates. Itraconazole and terbinafine are both safe and effective first-line agents, with reported overall cure rates of 50-90% for dermatophyte-related onychomycosis. Intermittent oral antifungal therapy may reduce the risk of systemic adverse effects and the cost of therapy; more study of this approach is needed. Oral antifungal agents offer patients with toenail onychomycosis greater likelihood of a cure than topical antifungals, but oral therapy carries greater risks and requires closer monitoring.
 



This article has been cited by other articles:


Home page
J. Am. Podiatr. Med. Assoc.Home page
M. A. Brenner, L. B. Harkless, R. W. Mendicino, and J. C. Page
Ciclopirox 8% Nail Lacquer Topical Solution for the Treatment of Onychomycosis in Patients with Diabetes: A Multicenter, Open-Label Study
J Am Podiatr Med Assoc, May 1, 2007; 97(3): 195 - 202.
[Abstract] [Full Text] [PDF]


Home page
Clin. DiabetesHome page
J. A. Winston and J. L. Miller
Treatment of Onychomycosis in Diabetic Patients
Clin. Diabetes, October 1, 2006; 24(4): 160 - 166.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Podiatr. Med. Assoc.Home page
D. P. Kalinowski, L. E. Edsberg, R. A. Hewson, R. H. Johnson, and M. S. Brogan
Low-Voltage Direct Current as a Fungicidal Agent for Treating Onychomycosis
J Am Podiatr Med Assoc, November 1, 2004; 94(6): 565 - 572.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Podiatr. Med. Assoc.Home page
M. A. Bodman, L. Feder, and A. M. Nace
Topical Treatments for Onychomycosis: A Historical Perspective
J Am Podiatr Med Assoc, March 1, 2003; 93(2): 136 - 141.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society of Health-System Pharmacists.